KaloBios Pharmaceuticals, Inc. (KBIO) saw a big move last session, as the company’s shares fell by more than 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for KBIO, as the stock is now down about 42% since Jan 15.
This biopharmaceutical company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (no increases or decreases), and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.
KBIO currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Better-ranked stocks in the same industry include Actavis plc (ACT) and Mallinckrodt plc (MNK). While Actavis carries a Zacks Rank #1 (Strong Buy), Mallinckrodt carries a Zacks Rank #2 (Buy). However, investors interested in the broader Medical Sector can consider Lannett Company, Inc. (LCI), which carries a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
KALOBIOS PHARMACEUTICALS INC (KBIO): Free Stock Analysis Report
Zacks Investment Research
- Personal Investing Ideas & Strategies
- Finance Trading